Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
Lücken schließen – Angebote ergänzen
Der Kooperationsverbund Gesundheitliche Chancengleichheit hat eine Handreichung zur Gesundheitsförderung mit Geflüchteten veröffentlicht. Die Broschüre führt in das Thema ein und formuliert grundlegende Handlungsoptionen. Ergänzt wird die Veröffentli...chung durch eine Zusammenstellung rechtlicher Grundlagen
more
Esta publicación integra la experiencia acumulada de la OPS y las buenas prácticas desarrolladas por sus Estados Miembros en los últimos años, incluidas las discusiones y experiencias compartidas en las reuniones regionales celebradas sobre el tema, y pone el acento en la innovación y la inclus...ión social. Esto requiere cambiar con urgencia los paradigmas tradicionales, partiendo de las acciones específicas que reducen gradualmente la incidencia de la TB para dirigirnos hacia acciones multisectoriales de eficacia demostrada en la contención rápida de la epidemia.
more
Documento de informação sintético
26 March 2021 Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.
Expressa Extensão Capa > v. 26, n. 1 (2021)
Este trabalho, abordar debates e questionamentos sobre a eficácia e a segurança da manipulação e aplicação das vacinas. Os autores perceben, nesse período de pandemia, onde aguarda-mos ansiosos por uma resposta da ciência em relação a uma vacin...a para o Covid-19, ressurge o debate antivacina.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
SBMFC Recommendations for PHC during the Pandemic of COVID-19 (edition 4)
This document answers questions and gives recommendations so that the Brazilian PHC can quickly receive the best possible scientific synthesis on the current situation of the pandemic of COVID-19
Analysis of fake news disseminated during the COVID-19 pandemic in Brazil
Lancet Glob Health 2021; 9: e782–92
Trata das orientações da vacinação dos grupos de pessoas com comorbidades, pessoas com deficiência permanente e gestantes e puérperas na Campanha Nacional de Vacinação contra a Covid-19, 2021.
Orientações sobre causas de mortes no contexto da covid-19 : respostas às perguntas mais frequentes
As perguntas, agrupadas em blocos nesta publicação, foram realizadas durante as videoconferências de apresentação das novas orientações e no decorrer do processo de trabalho, pelos profissi...onais codificadores e gestores do Sistema de Informações sobre Mortalidade (SIM) nas esferas estaduais e municipais.
more
Introduction: Considering the global prevalence of coronavirus disease 2019 (COVID-19), a vaccine is being developed to control the disease as a complementary solution to hygiene measures—and better, in social terms, than social distancing. Given that a vaccine will eventually be produced, informa...tion will be needed to support a potential campaign to promote vaccination.
Objective: The aim of this study was to determine the variables affecting the likelihood of refusal and indecision toward a vaccine against COVID-19 and to determine the acceptance of the vaccine for different scenarios of effectiveness and side effects.
Materials and Methods: A multinomial logistic regression method based on the Health Belief Model was used to estimate the current methodology, using data obtained by an online anonymous survey of 370 respondents in Chile.
Results: The results indicate that 49% of respondents were willing to be vaccinated, with 28% undecided or 77% of individuals who would potentially be willing to be inoculated. The main variables that explained the probability of rejection or indecision were associated with the severity of COVID-19, such as, the side effects and effectiveness of the vaccine; perceived benefits, including immunity, decreased fear of contagion, and the protection of oneself and the environment; action signals, such as, responses from ones' family and the government, available information, and specialists' recommendations; and susceptibility, including the contagion rate per 1,000 inhabitants and relatives with COVID-19, among others. Our analysis of hypothetical vaccine scenarios revealed that individuals preferred less risky vaccines in terms of fewer side effects, rather than effectiveness. Additionally, the variables that explained the indecision toward or rejection of a potential COVID-19 vaccine could be used in designing public health policies.
Conclusions: We discovered that it is necessary to formulate specific, differentiated vaccination-promotion strategies for the anti-vaccine and undecided groups based on the factors that explain the probability of individuals refusing or expressing hesitation toward vaccination.
more
La miocarditis es una enfermedad inflamatoria con compromiso focal o difuso del miocardio, que se presenta de forma fulminante, pudiendo ser aguda, subaguda o crónica.Las que poseen un nivel de gravedad suficiente para reconocerlas clínicamente, son raras, pero la prevalencia de los casos leves y ...asintomáticos probablemente sea más elevada.
more